METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis study tests a two-step treatment plan for men with advanced prostate cancer that has stopped responding to standard hormone therapy. First, patients receive a combination of testosterone and an experimental drug called ZEN-3694, followed by a mix of enzalutamide and ZEN-3694…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 26, 2026 04:23 UTC
-
New hope for Hard-to-Treat prostate cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug, BMS-986365, against standard treatments (chemotherapy or another hormone therapy) in men with metastatic castration-resistant prostate cancer, a type that has spread and stopped responding to hormone therapy. About 960 participants will be randomly as…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 26, 2026 04:22 UTC
-
Two-Drug combo aims to supercharge immune attack on prostate cancer
Disease control Recruiting nowThis study tests whether adding bipolar androgen therapy (BAT) to the standard Sipuleucel-T vaccine can strengthen the immune system's fight against metastatic castration-resistant prostate cancer. About 26 men will receive both treatments, and researchers will measure immune res…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 26, 2026 04:21 UTC
-
Can a cancer drug shrink prostate tumors in men with a specific gene change?
Disease control Recruiting nowThis study tests the drug bortezomib in men with advanced prostate cancer that has spread and no longer responds to hormone therapy, specifically those with a missing PTEN gene. The main goal is to see if the drug can lower PSA levels by at least 30%. Participants receive bortezo…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New drug DS9051b enters first human trials for rare adrenal and prostate cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called DS9051b in people with advanced adrenocortical carcinoma (a rare adrenal gland cancer) or metastatic castration-resistant prostate cancer. The main goals are to check the drug's safety and find the right dose. About 40 adults wi…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
New drug combo aims to extend life in tough prostate cancer
Disease control Recruiting nowThis study tests whether adding xaluritamig to standard abiraterone therapy helps men with metastatic castration-resistant prostate cancer live longer. About 750 participants who have not had chemotherapy will be randomly assigned to receive the combination or another standard tr…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new injectable radioactive drug, Actinium-225 rhPSMA-10.1, in 60 men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug aims to find and destroy cancer cells with radiation. Researchers will check safety and tu…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: University College, London • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
New radiation therapy targets hard-to-treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called 177Lu-rhPSMA-10.1 in men with metastatic castrate-resistant prostate cancer, a type of prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The study has two phases: Pha…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding darolutamide to standard treatments (like chemotherapy or targeted therapy) can help men with a hard-to-treat form of advanced prostate cancer live longer without their cancer getting worse. About 162 participants will receive either standard care …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New radiation therapy aims to slow advanced prostate cancer
Disease control Recruiting nowThis study tests a new drug (lutetium rosopatamab) that delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. The trial compares the new drug plus standard care versus s…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
New drug combo targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see if it helps control the can…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug cocktail aims to outsmart resistant prostate cancer
Disease control Recruiting nowThis study tests whether a combination of two drugs (inavolisib and enzalutamide) works better than standard treatments for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. About 100 men will be randomly assigned to receive eith…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New hope for tough prostate cancer: daily pill aims to control disease after standard treatment fails
Disease control Recruiting nowThis study tests a daily oral drug called XL092 in people with advanced prostate cancer that has spread and is no longer responding to a specific type of radiation therapy (Lu-177). The main goal is to see if the drug can stop the cancer from growing for at least 16 weeks. About …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New hope for advanced prostate cancer: BNT324 faces off against chemo in major trial
Disease control Recruiting nowThis study compares a new drug, BNT324, to standard chemotherapy (docetaxel plus steroids) in men with metastatic castration-resistant prostate cancer that has progressed after prior hormone therapy. The goal is to see if BNT324 helps patients live longer and delays cancer growth…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug combo aims to control advanced breast cancer
Disease control Recruiting nowThis study tests a new drug called GVV858, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer or other solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can help control the disease. About 205 ad…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:14 UTC
-
Promising new radiation therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new radioactive drug (177Lu-P17-087/088) in 30 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug seeks out cancer cells and delivers radiation directly to them. The study first checks safety and ho…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
Real-world study tracks Pluvicto's safety in korean prostate cancer patients
Disease control Recruiting nowThis study is checking how safe and effective Pluvicto is for men with advanced prostate cancer that no longer responds to hormone therapy. About 278 participants in South Korea will be followed during their regular treatment. The main goal is to track any side effects and see ho…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:13 UTC
-
New hope for Hard-to-Treat prostate cancer: JANX007 enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug, JANX007, in men with metastatic castration-resistant prostate cancer that has worsened after other treatments. The main goals are to check safety and find the right dose. About 272 participants will receive the drug to see if it can help c…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New drug duo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThis study tests two experimental drugs, REGN4336 and REGN5678, in people with advanced prostate cancer that has spread and stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 228 participants will take par…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New hope for tough prostate cancer: combo therapy trial launches
Disease control Recruiting nowThis study tests whether adding an experimental drug (ZEN003694) to the standard drug enzalutamide can help men with a hard-to-treat type of prostate cancer that has spread and stopped responding to another treatment. About 200 men will be randomly assigned to get either the comb…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated May 26, 2026 04:12 UTC
-
New combo therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study is for men with a type of advanced prostate cancer that has spread and is no longer controlled by hormone therapy. The researchers are testing a combination of two drugs: cabozantinib (a pill that blocks cancer growth) and a radioactive drug called 177Lu-PSMA-617 (whic…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
New combo therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new treatment called SYNC-T therapy (SV-102) for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to hormone therapy. The goal is to find the safest and most effective dose and see if it can shrink tumors or slow the …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syncromune, Inc. • Aim: Disease control
Last updated May 26, 2026 03:57 UTC
-
New combo aims to boost radiation therapy for advanced prostate cancer
Disease control Recruiting nowThis study tests whether giving a drug called abemaciclib before a targeted radiation therapy (177Lu-PSMA-617) can make the radiation work better for men with advanced prostate cancer that has stopped responding to other treatments. About 30 participants will receive the combinat…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Vadim S Koshkin • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Can a second dose of targeted radiation keep prostate cancer in check?
Disease control Recruiting nowThis study looks at whether giving a second course of a targeted radiation drug (Lu-PSMA) can help men with advanced prostate cancer that has stopped responding to hormone therapy. About 58 men who previously benefited from this treatment will receive it again. The goal is to see…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
New combo aims to slow advanced prostate cancer
Disease control Recruiting nowThis study tests if adding an experimental drug (PF-06821497) to the standard treatment enzalutamide works better than enzalutamide alone for men with a type of advanced prostate cancer that no longer responds to hormone therapy. About 900 participants will receive either the com…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New hope for Hard-to-Treat prostate cancer: first human trial launches
Disease control Recruiting nowThis early-stage study tests an experimental drug called ABBV-969 in about 230 men with a type of advanced prostate cancer that no longer responds to hormone therapy. The main goals are to check the drug's safety, find the best dose, and see if it can lower PSA levels (a marker o…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New shot could replace daily pills for prostate cancer patients
Disease control Recruiting nowThis study tests a new injectable drug, ASP5541, for men with advanced prostate cancer that has spread. The drug is a different form of the standard treatment abiraterone, given as a shot every 12 weeks instead of daily pills. The study will compare how well the injection works a…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage study tests a new drug, JANX014, in 43 men with a hard-to-treat type of prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The main goals are to check the drug's safety and find the right dose, while also looking …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janux Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New prostate cancer drug trial opens for chinese men
Disease control Recruiting nowThis early-stage study tests a new drug called ASP5541 in about 12 Chinese men whose prostate cancer has spread. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to check the drug's safety and how it moves…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for advanced prostate cancer: extended targeted radiation therapy under study
Disease control Recruiting nowThis study tests a longer course of a targeted radiation drug (lutetium-177) in adults with a type of advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if giving up to 12 cycles is safe and how the radiation affects the body. About 106 pa…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New pill shows promise against tough prostate cancer in early trial
Disease control Recruiting nowThis study tests an experimental daily pill called HP518 in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to check the drug's safety, find the best dose, and see if it can shrink tumors or …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Hinova Pharmaceuticals Inc. • Aim: Disease control
Last updated May 22, 2026 14:00 UTC
-
New cell therapy takes on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment called A-CAR032 for men with a tough-to-treat type of advanced prostate cancer that has stopped responding to standard hormone therapy. The study aims to see if the treatment is safe and to get an early look at whether it can shrink tu…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai AbelZeta Ltd. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new drug called FG-3246 in 75 men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. The drug is designed to find and attack cancer cells while sparing healthy ones. The goal is to see if it can slow cancer growth and i…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Kyntra Bio • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Supercharged immune cells take on End-Stage prostate cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment for men with advanced prostate cancer that has spread to the bone and stopped responding to standard therapies. The approach takes a patient's own immune cells (gamma delta T cells), genetically modifies them to recognize and attack pr…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New hope for Hard-to-Treat prostate cancer: early trial launches
Disease control Recruiting nowThis early-stage study tests an experimental drug called BMS-986460 in men with metastatic castration-resistant prostate cancer, a type of prostate cancer that has spread and stopped responding to standard hormone therapy. The main goals are to check the drug's safety and find th…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug called HRS-5041 in 25 men with metastatic castration-resistant prostate cancer (cancer that has spread and stopped responding to hormone therapy). The main goal is to check the drug's safety and how the body processes it. Participants will …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Atridia Pty Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new drug called Dato-DXd, either alone or with other cancer drugs, in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gastric, prost…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for tough prostate cancer: first human trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called AZD2284 (and related compounds) in people with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goal is to check safety and find the right dose. About 136 participant…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 20, 2026 11:53 UTC
-
Could adding platinum to chemo stop prostate cancer from spreading?
Disease control Recruiting nowThis study is for men with advanced prostate cancer that no longer responds to hormone therapy and has certain DNA repair gene changes. It tests whether adding a platinum drug to the usual chemo (docetaxel) can delay cancer growth or spread. About 236 participants will be randoml…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New drug combo aims to slow advanced prostate cancer
Disease control Recruiting nowThis study tests whether combining two drugs—pembrolizumab (an immunotherapy) and 177Lu-PSMA-617 (a targeted radiation therapy)—can slow the growth of advanced prostate cancer that has stopped responding to hormone treatments. About 48 men with metastatic castration-resistant pro…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New combo drug trial aims to control hard-to-treat prostate cancer
Disease control Recruiting nowThis early-stage trial tests whether adding valemetostat to the standard drug darolutamide is safe and tolerable for men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. About 60 adu…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 18, 2026 12:07 UTC
-
New drug cocktails aim to tame tough prostate cancer
Disease control Recruiting nowThis study tests whether combining the immunotherapy drug pembrolizumab with other treatments can help men with a hard-to-treat form of prostate cancer that has spread and stopped responding to hormone therapy. About 1,200 participants will receive different drug combinations acr…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New shot every 12 weeks aims to control advanced prostate cancer
Disease control Recruiting nowThis study tests a new medicine called PRL-02 depot, given as a shot into the muscle every 12 weeks, to lower testosterone in men with advanced prostate cancer. The goal is to find a safe dose and see if it works alone or with another drug, enzalutamide. About 174 men whose cance…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
Hormone cycling: a new hope for prostate cancer control?
Disease control Recruiting nowThis study tests a new treatment approach for men with metastatic prostate cancer that has stopped responding to standard hormone therapy. It alternates high-dose testosterone with a drug called darolutamide to see if this cycling can keep the cancer under control longer. About 6…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Hormone boost followed by radiation: new hope for Hard-to-Treat prostate cancer?
Disease control Recruiting nowThis study tests if giving high-dose testosterone followed by a targeted radiation drug can help men with a tough-to-treat type of prostate cancer that has spread. About 12 participants will take the study drugs for 3.5 months and be followed for 6 months total. The goal is to se…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New radiation therapy aims to shrink tough prostate cancers
Disease control Recruiting nowThis study is for people with metastatic prostate cancer that has spread and is no longer controlled by hormone therapy. It tests a new drug called [212Pb]Pb-ADVC001, which delivers a precise dose of radiation directly to cancer cells. The goal is to find the safest and most effe…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for tough prostate cancer: first human trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called [225Ac]Ac-FL-020 in 50 people with a hard-to-treat type of prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check the drug's safety and find the right dose. The drug works by targeting …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Full-Life Technologies GmbH • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
New drug FOG-001 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, FOG-001, in about 595 people with advanced solid tumors that have not responded to other treatments. The goal is to see if FOG-001 is safe and can shrink tumors or slow their growth. The trial focuses on several cancer types, including colorectal, pro…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New hope for men with hard-to-treat prostate cancer: combo therapy enters trial
Disease control Recruiting nowThis study tests a new drug combination (SX-682 plus enzalutamide) in 53 men with metastatic castration-resistant prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the combo can shrink tumors, lower PSA levels, or keep the disease st…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated May 06, 2026 16:14 UTC
-
New imaging test could sharpen view of prostate cancer
Diagnosis Recruiting nowThis study tests a new type of PET scan (18F-DCFPyL-PSMA) to see how well it shows prostate cancer in 30 men with advanced disease who are already scheduled for a targeted radiation therapy. The goal is to compare this scan with the standard one to see if it detects cancer spots …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Diagnosis
Last updated May 26, 2026 04:13 UTC
-
New study tracks Real-Life impact of targeted radiation on prostate cancer Patients' daily lives
Symptom relief Recruiting nowThis study follows 500 men with metastatic castration-resistant prostate cancer who are receiving a targeted radiation therapy called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how the treatment affects their quality of life, pain, and disease progression in every…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Symptom relief
Last updated May 22, 2026 14:01 UTC
-
Real-World study tracks Olaparib's impact on tough prostate cancer
Knowledge-focused Recruiting nowThis study follows 300 men with metastatic castration-resistant prostate cancer who are taking olaparib as part of their normal treatment. Researchers want to see how long patients stay on the drug, how well it controls the cancer, and what side effects occur. The goal is to lear…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 26, 2026 04:20 UTC
-
New study tracks Real-Life results of Two-Drug combo for advanced prostate cancer
Knowledge-focused Recruiting nowThis study watches 250 men with metastatic castration-resistant prostate cancer who are already taking olaparib plus abiraterone as part of their normal care. Researchers will track how long patients stay on the treatment and what treatments they need next. The goal is to underst…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated May 26, 2026 04:14 UTC
-
Gut bug may predict prostate cancer drug response
Knowledge-focused Recruiting nowThis study looks at whether a specific gut bacterium, Akkermansia muciniphila, can help predict how well men with advanced prostate cancer respond to a common hormone therapy (abiraterone acetate). Researchers will measure levels of this bacterium in stool samples before and afte…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 26, 2026 04:13 UTC
-
5,000 men with advanced prostate cancer to be tracked in major new registry study
Knowledge-focused Recruiting nowThis study is a registry that will follow 5,000 men with prostate cancer that has come back or spread. The goal is to see what treatments doctors actually use and how the disease progresses over time. Participants are grouped by their cancer stage, from early PSA recurrence to ad…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: UroTrials Company (GmbH) • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC
-
New study tracks how Lutetium-177 works in real life for prostate cancer patients
Knowledge-focused Recruiting nowThis study observes 300 adults with metastatic castration-resistant prostate cancer who are receiving a radioactive drug called lutetium-177. Researchers will track how long the treatment controls the cancer and any side effects in everyday medical practice, not in a controlled l…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated May 20, 2026 11:55 UTC
-
New PET tracer could reveal which tumors respond to immunotherapy
Knowledge-focused Recruiting nowThis study tests a new radioactive tracer called 64Cu-GRIP B, which attaches to a protein (granzyme B) made by immune cells. By using PET scans, doctors hope to see which tumors are responding to immunotherapy. The trial involves about 91 adults with advanced prostate, kidney, or…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Rahul Aggarwal • Aim: Knowledge-focused
Last updated May 20, 2026 11:53 UTC